Association between medicine Price declaration by pharmaceutical industries and retail prices in Malaysia’s private healthcare sector

Nur Sufiza Ahmad1,2, Ernieda Hatah1* and Mohd Makmor-Bakry1

Abstract

Background: As part of the initiatives to increase price transparency for consumers, pharmaceutical industry in Malaysia have been encouraged to declare the wholesale and recommended retail prices (RRP) of medicines to the Pharmaceutical Service Department (PSD) yearly. However, the relationship between the voluntary price reporting practices and consumers’ retail medicine price is unknown. Therefore, this study aims to evaluate the effect of the voluntary price reporting practice of pharmaceutical industry on retail medicine prices, factors that may affect consumer medicine prices in Malaysia’s private healthcare sector, and the retail medicine pricing trend over 2011–2015.

Methods: A yearly correlation test for a 5-year period was performed to investigate the association between the wholesale and RRP medicine prices declared by the pharmaceutical industry from 2011 to 2015 on the one hand and the consumer wholesale and retail medicine price database on the other hand. The median price ratio (MPR) was calculated by comparing the consumer retail medicine price to its international reference price. The Kruskal Wallis test was used to analyse the pricing trend throughout the 5-year period, and factors that might elevate the MPR above 2.5 were modelled using binary logistic regression.

Results: A total of 2527 medicine price data were analysed. There was a strong significant association between medicine prices declared to the PSD and the retail medicine prices in every year of the 5-year period. Moreover, there was no significant increase in retail medicine prices throughout the 5-year period. The medicine types, retail location, type of manufacturer, medicinal indications, declared wholesale and RRP’s significantly influenced the consumer MPRs that where > 2.5.

Conclusion: The declared medicine price was found to have a significant association with the consumer retail medicine price. Thus, it may be a useful reference for consumers purchasing medicines in private healthcare settings. However, the government of Malaysia must develop strategies to increase medicine price transparency for price-control mechanisms in the private healthcare sector.

Keywords: Transparency, Pharmaceutical pricing, Drugs, Affordability, Price information, Policy

* Correspondence: ernieda@ukm.edu.my

1Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia

Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The Malaysian healthcare system consists of public and private healthcare providers, who are independent of each other. The public healthcare sector, which is the main provider of healthcare services in Malaysia, is funded through the Consolidated Revenue Fund managed by the Ministry of Finance, while the private healthcare sector is funded by consumer out-of-pocket payments, private health insurance, and employer benefit schemes [1]. Government tax exemptions and incentives are only granted to hospitals that provide medical tourism [2]. The ratio of healthcare spending between the public and private sectors was reported as 52:48 [3]. In 2014, healthcare expenditure in Malaysia was RM 49.73 billion (USD 15.64 billion), with private spending accounting for RM 23.92 billion (USD 7.52 billion) [4]. In public healthcare facilities, patients are only charged a nominal fee of RM 1 (USD 0.31) to RM 5 (USD 1.57) for each outpatient visit, while the fees in private healthcare facilities are usually higher [5]. In the public healthcare sector, containment of medicine prices is achieved by bulk purchase through concession supply and national tender. Prices are usually set using internal and external reference pricing mechanisms [5]. These pricing mechanisms involve comparing the price with other medicines in the same therapeutic group, or comparing purchase prices in public healthcare institutions with the international reference prices (IRP) [5]. Conversely, in the private healthcare sector, only the doctor’s consultation fees are regulated by the government. Thus, the prices of medicines in the private healthcare sector are reported to be variable and highly augmented [6].

A previous study by Babar et al. [6] in Malaysia regarding the pricing of 48 medicines in 32 community pharmacies and 20 dispensing doctors showed that the prices of innovator brands (IB) and generic medicines were at least 15 and 6.6 times higher, respectively, than their international reference prices (IRPs). The price markup in dispensing doctors’ clinics ranged between 50 and 76% for IBs, and could be up to 316% for generics. In retail pharmacies, the markup price ranged between 25 and 38%, and 100 and 140% for IBs and generics, respectively [6]. In another study, the medicine prices in retail pharmacies in the northern region of Malaysia were found to be higher than the mean retail price in Australia [7]. The high prices of medicines may reduce accessibility and affordability, which may affect the consumer’s decision to purchase medicines, leading to poor healthcare quality and irrational use of medicines [8].

There is, therefore, a need for the Malaysian government to structure a scheme for rational pricing of medicines in the private healthcare sector. As part of the initiative to ensure adequate, continuous, and equitable access to high-quality, safe, effective, and affordable medicines, Malaysia’s Ministry of Health (MOH) has developed a National Medicine Policy (MNMP) that encourages initiatives to increase transparent medicine pricing in Malaysia, and provide consumers with relevant and readily available information [9]. Hence, in 2011, the MOH began encouraging pharmaceutical companies to voluntarily declare their wholesale and recommended retail price (RRP) to the Pharmaceutical Service Division (PSD) [9]. The declared prices were then used to develop the RRP database that was published on the PSD website, to be used as a guide during medication purchasing by consumers [9]. The declared wholesale prices were used only for monitoring purposes by the PSD and were not made available to the public. This initiative has previously been adopted by Canada and several European countries such as Austria, Bulgaria, Cyprus, Lithuania, and France, who requested their pharmaceutical industries to declare ex-factory drug prices to the government, which are then used during price negotiations [10, 11]. Price transparency was reported to provide consumers with options, thus allowing for more efficient and effective procurement [12].

In the long term, it may lead to reduce medicine prices through healthy competition, thus increasing consumer access to affordable medicines.

In Malaysia, although the voluntary reporting practice has been implemented for several years, no study has evaluated how the practice influences retail medicine prices. Thus, we investigated: 1) the association between medicine prices declared to the PSD and retail prices, 2) factors that may influence the construct of retail medicine prices in the private healthcare setting in Malaysia, and 3) the retail medicine price trend from 2011 to 2015.

Methods

The investigations were performed using the PSD medicine price database from 2011 to 2015, which consisted of: 1) the wholesale and RRP prices of controlled and over-the-counter medicines, as declared by pharmaceutical companies, and 2) consumer wholesale and retail medicine prices (sampled by the PSD through the Medicine Price Monitoring Survey (MPMS) at institutional counters or from medicine invoices, or both) [13]. The MPMS reviewed prices of medicines commonly used for acute and chronic diseases (consisting of 25 core and 32 supplementary medicines), listed by the World Health Organization (WHO). The national MPMS is conducted yearly following the recommended methodology of the WHO for “baskets of medicines” in the public and private healthcare sectors, such as community pharmacies and private hospitals, in both urban and rural areas of Malaysia [14]. Hence, in the MPMS database, the same brand of a medicine referred to by the names given to them by their manufacturers (pharmaceutical companies) (e.g., Norvasc® is the brand name for the drug whose generic name is Amlodipine) may have a variety of prices from their multiple sampling
sites. Because of that, the median price of the medicine brand was used for analysis in this study. Unlike the RRP medicine database which published to the public, the MPMS was only used by the PSD for monitoring purposes.

Only medicines listed in all three databases (the MPMS database; the database of medicine prices declared to PSD; and the International Reference Prices (IRP) database, which contains information on median buyer prices) [15] were included in this study. According to the brand names of the medicines, the following data were extracted from the databases: medicine prices, manufacturers’ category (local or imported), type of medicine (innovator brand [IB] [patented versions of the chemical entity first launched in the international market] or generic), classification (acute or chronic condition), location of MPMS sampling (e.g., Peninsular, East Malaysia, urban or rural area), and setting (community pharmacies or private hospitals). For all medicines, the unit drug price was calculated by dividing the drug-pack selling price by the number of tablets, capsules, vials, or doses it contained.

We obtained the Spearman correlation coefficient using the statistical package for the social sciences (SPSS) software (version 22.0; SPSS Inc., Chicago, IL, USA) to analyse the relationship between the prices declared to the PSD and retail medicine prices. The correlation test was performed for each year due to the limited number of medicines prices available throughout the 5-year period. \( p < 0.05 \) was considered statically significant. The difference between the retail prices, and the wholesale and RRP medicine prices was determined by the mean percentage difference. While the median price ratio (MPR) was calculated by comparing the median unit retail price to the median unit price in the IRP [14]. The IRP was converted to local currency using the average Bank Negara exchange rate for each year of the study. The following average USD exchange rates were used for 2011 to 2015: RM 3.00 (2011), RM 3.17 (2012), RM 3.19 (2012), RM 3.18 (2014), and RM 3.96 (2015). An MPR of 1 indicates the consumer price is equivalent to the IRP. In this study, an MPR \(< 2.5\) is considered as an acceptable retail medicine price in the private healthcare settings [16]. Retail medicine price trends were evaluated for medicines with pricing data reported continuously from 2011 to 2015. Using the Kruskal-Wallis test, the median retail price difference between the years was evaluated.

Factors that might influence the consumer retail prices with \( \text{MPR} > 2.5\) were investigated using a binary logistic regression method with a backward likelihood-ratio analysis. Variables of interest such as settings, location, manufacturers’ category, type of dosage (tablet or others), originality, and price declared to the PSD were investigated, and those with \( p < 0.05 \) were considered to have significantly affected the consumer retail prices with \( \text{MPR} > 2.5\). Prior to this evaluation, a univariate analysis was performed to determine the variables to be included in the final model analysis. Only those with \( p < 0.25 \) were included.

**Results**

The yearly voluntary reporting of medicine prices by pharmaceutical companies was inconsistent. Based on the availability of medicine price data in the three databases, only 81 drug groups (e.g. Glibenclamide) and 237 brands (e.g. Daonil”) were included in the current study. Of these, the prices of only 15 medicine brands were consistently declared to the PSD from 2011 to 2015. Details of the medicines investigated in this study, presented according to their use (chronic and acute conditions), are mentioned in Additional file 1.

The wholesale price and declared RRP from 2011 to 2015 are significantly associated with the retail price (\( p < 0.05 \)) (Table 1). For every year, all correlations were found to be strongly related, with correlation coefficients \( > 0.7\). The percentage of medicine price markup from the declared PSD wholesale and wholesale price in MPMS to retail prices for 2011 to 2015 is presented in Table 2. The results showed that generic medicines always had a higher percentage of median price markups (53.1–110.8%) compared with the IB medicines (4.1–26.9%) (Table 2). Interestingly, markups of the wholesale medicine prices, deduced using MPMS retail prices, were always higher than the markups calculated from the wholesale price declared to the PSD.

A summary of the calculated MPR from 2011 to 2015 is shown in Table 3. The results show that most of the medicines included in the study had an MPR > 2.5. IB medicines were found to have a higher median MPR than their generic counterparts. The median MPR was found to be the highest in 2015 for both IBs (MPR 28.3) and generics (MPR 10.6). The 25th and 75th percentiles for IBs and generics were 8.0 and 40.4, and 4.2 and 18.1, respectively. Nevertheless, analysis of the retail medicine price for 15 medicine brands showed no significant increase in their retail medicine price for both IBs and generics throughout the 5-year period (\( P > 0.05 \)) (Table 4). The model analysis (Table 5) revealed that the factors that might influence the medicines retail prices with MPR > 2.5 were: chronic disease use, locally manufactured, and sold in East Malaysia (\( p < 0.05 \)). Moreover, generic medicines, medicines in rural areas, and medicines in other forms were less likely to have an MPR > 2.5. Interestingly an increase in the price of a single dose unit medicine RRP declared to the PSD by RM 0.01 (USD 0.003) increased the chances of a retail medicine having an MPR > 2.5 by 52% (OR, 1.52; 95% CI, 1.17 to 1.98; \( p < .05 \)). Moreover, an RM 0.01 (USD 0.003) reduction in the retail wholesale price increased the chances of medicines having an MPR > 2.5 by 72% (OR, 0.72; 95% CI, 0.55 to 0.93; \( p = 0.013 \)).
Discussion
Voluntary medicine price declaration by pharmaceutical companies had a strong and significant association with private healthcare sector retail prices. Because the declared RRP and median retail prices were significantly associated, the declared prices published in the PSD website can be considered reliable medicine pricing information for consumers. Accurate information on medicine prices is useful to consumers as it will provide them with options, thus, allowing for more efficient and effective procurement [12]. The latter may empower consumers and result in market competition, which may lead to reduced medicine retail price in the long run [12]. Meanwhile, the information about the significant association between the disclosure of wholesale medicine prices to the government and retail prices can be used for direct negotiations on agreed medicine prices with drug companies, as currently practiced in Canada and certain European countries [10, 11]. Nevertheless, only a few pharmaceutical companies declared their medicine prices to the PSD. Although various efforts have been made and numerous discussions have been held between government stakeholders and pharmaceutical industry representatives, price data for only 2527 medicines between 2011 and 2015 were available to be used in the study. Moreover, the data of only 15 medicine brands were consistently reported throughout the 5-year period. To increase the pharmaceutical industries practice of medicine price transparency, similar to South Africa, Vietnam, and some European countries, the government may want to include price disclosure in the pharmaceutical pricing regulations [17–19].

In this study, the median retail price of generic medicines had a higher percentage markup (up to 75% of their declared PSD wholesale price) than IB medicines. Nevertheless, when the retail prices were compared to the IRP, the median MPR for generic medicines was lower than that of IB. This shows that generic medicines in the private healthcare sector, although highly marked up, were more affordable than IB medicines. This is supported by the findings of Ahmad et al. [13], who reported that the affordability of 11 essential generic medicines reviewed in their study was better than that of IB medicines. In their study, treatment with generic medicines cost less than 2 days’ wages, while with IB, it cost 0.3 to 7 days’ wages [13]. The high median markup of retail prices may be attributable to the low baseline cost of generic medicines,

Table 1  The relationship between prices declared to Pharmaceutical Service Division and retail medicine price

| Year | Correlation coefficient, $\rho$ | p-value | Correlation coefficient, $\rho$ | p-value |
|------|-------------------------------|---------|-------------------------------|---------|
| 2011 | 0.92                          | $p < 0.01$ | 0.96                          | $p < 0.01$ |
| 2012 | 0.89                          | $p < 0.01$ | 0.89                          | $p < 0.01$ |
| 2013 | 0.92                          | $p < 0.01$ | 0.91                          | $p < 0.01$ |
| 2014 | 0.89                          | $p < 0.01$ | 0.89                          | $p < 0.01$ |
| 2015 | 0.75                          | $p < 0.01$ | 0.86                          | $p < 0.01$ |

Table 2  Percentage of medicine price markup from declared wholesale and retail wholesale to median retail price

| Type of medicine | Year | Number of medicines brands reviewed | Number of pricing data from MPMS | Percentage price markup (%) | From declared wholesale to median retail price | From median wholesale price to median retail price |
|------------------|------|------------------------------------|----------------------------------|-----------------------------|---------------------------------------------|-------------------------------------------------|
|                  |      |                                    |                                  | Median | 25th percentile | 75th percentile | Median | 25th percentile | 75th percentile |
| Innovator        | 2011 | 30                                  | 187                              | 26.9   | 16.9           | 33.4           | 33.3   | 26.3           | 37.5           |
|                  | 2012 | 12                                  | 103                              | 14.8   | 3.0            | 32.7           | 33.32  | 39.5           | 28.6           |
|                  | 2013 | 17                                  | 182                              | 9.3    | −6.3           | 29.6           | 38.9   | 33.3           | 45.8           |
|                  | 2014 | 10                                  | 176                              | 18.3   | −5.3           | 33.3           | 32.9   | 30.9           | 33.3           |
|                  | 2015 | 19                                  | 235                              | 4.1    | −2.9           | 32.8           | 33.4   | 29.4           | 47.1           |
| Generic          | 2011 | 44                                  | 176                              | 53.1   | 18.9           | 179.0          | 100.9  | 56.3           | 181.8          |
|                  | 2012 | 22                                  | 105                              | 109.2  | 39.5           | 284.1          | 138.0  | 70.4           | 308.2          |
|                  | 2013 | 48                                  | 194                              | 110.8  | 37.0           | 248.1          | 102.6  | 66.7           | 177.8          |
|                  | 2014 | 68                                  | 383                              | 95.1   | 23.2           | 200.8          | 117.9  | 65.5           | 255.9          |
|                  | 2015 | 149                                 | 786                              | 82.7   | 20.0           | 229.7          | 102.9  | 63.7           | 203.0          |

Note: MPMS Medicine Price Monitoring Survey

*Declared wholesale = the wholesale price declared by the pharmaceutical industries to Pharmaceutical Service Division (PSD), Ministry of Health Malaysia*

*Median wholesale and retail price = medicine price sampled by the MPMS from various community pharmacy and private hospitals in Malaysia*
offering an opportunity to gain higher profit margins, as reported in previous local and non-local studies [6, 20–22]. Furthermore, the increased likelihood of an MPR being > 2.5 with an RM 0.01 reduction in the wholesale price declared to the PSD may also be attributable to the same reasons. Although there is no medicine price control in the private healthcare sector in Malaysia, the median retail price for 15 medicine brands (5 IBs and 10 generics) was not significantly different throughout the 5-year period. Regardless, a majority of medicine prices in private facilities were found to have an MPR > 2.5.

The current study evaluated the constructs for medicine price in private healthcare settings with consideration on the price declaration practice by the pharmaceutical industries. The data included in the analysis involved large data set and many variables were investigated to evaluate the retail medicine prices which were analyzed as MPR. The MPR threshold of 2.5 was used in this study as an

| Table 3 | Summary of median price range (MPR) of medicines in private healthcare sector in Malaysia from 2011 to 2015 (n = 2527) |
|---|---|
| **Year** | **MPR > 2.5 n (%)** | **MPR ≤ 2.5 n (%)** | **Innovator Brand Median MPR 25th percentile 75th percentile** | **Generic medicine Median MPR 25th percentile 75th percentile** |
| 2011 | 337 (92.8) | 26 (7.2) | 20.2 6.4 37.7 | 8.7 4.5 16.2 |
| 2012 | 194 (93.3) | 14 (6.7) | 20.3 5.8 62.7 | 6.0 3.2 10.9 |
| 2013 | 368 (97.9) | 8 (2.1) | 25.2 4.4 39.6 | 7.4 4.6 11.6 |
| 2014 | 520 (93.0) | 39 (7.0) | 10.3 5.6 29.9 | 8.5 3.6 17.6 |
| 2015 | 906 (88.7) | 115 (11.3) | 28.3 8.0 40.4 | 10.6 4.2 18.1 |

**Note:** MPR Median Price Range

The current study evaluated the constructs for medicine price in private healthcare settings with consideration on the price declaration practice by the pharmaceutical industries. The data included in the analysis involved large data set and many variables were investigated to evaluate the retail medicine prices which were analyzed as MPR. The MPR threshold of 2.5 was used in this study as an

| Table 4 | The median retail price for 15 medicine brands from year 2011 to 2015 |
|---|---|
| **Year** | **MPMS retail price** for sample of medicine from 2011 to 2015 (RM) |
| 2011 | 2012 | 2013 | 2014 | 2015 |
| **Generic name** | Median | 25th | 75th | Median | 25th | 75th | Median | 25th | 75th | Median | 25th | 75th |

**Innovator**

| Hyoscine butylbromide 10 mg tablet | 0.35 | 0.32 | 0.40 | 0.33 | 0.30 | 0.40 | 0.32 | 0.30 | 0.40 | 0.47 | 0.30 | 0.45 |
| Glibenclamide 5 mg tablet | 0.84 | 0.73 | 0.90 | 0.65 | 0.60 | 0.84 | 0.75 | 0.65 | 0.84 | 0.76 | 0.65 | 0.83 |
| Gliclazide 80 mg tablet | 1.33 | 1.10 | 1.51 | 1.24 | 1.00 | 1.50 | 1.17 | 1.08 | 1.50 | 1.20 | 1.01 | 1.50 |
| Metformin 500 mg tablet | 0.53 | 0.40 | 0.72 | 0.48 | 0.45 | 0.55 | 0.49 | 0.45 | 0.53 | 0.43 | 0.39 | 0.50 |
| Frusemide 40 mg tablet | 1.21 | 1.18 | 1.26 | 1.20 | 1.18 | 1.20 | 1.23 | 1.20 | 1.38 | 1.20 | 1.19 | 1.26 |

**Generic**

| Allopurinol 300 mg tablet | 0.40 | 0.35 | 0.45 | 0.43 | 0.35 | 0.50 | 0.40 | 0.35 | 0.45 | 0.40 | 0.30 | 0.50 |
| Isosorbide dinitrate 10 mg tablet | 0.10 | 0.10 | 0.15 | 0.15 | 0.10 | 0.20 | 0.20 | 0.20 | 0.20 | 0.16 | 0.26 | 0.20 |
| Amoxicillin 250 mg tablet | 0.20 | 0.20 | 0.25 | 0.20 | 0.20 | 0.25 | 0.20 | 0.20 | 0.20 | 0.20 | 0.25 | 0.22 |
| Diclofenac 100 | 0.42 | 0.35 | 0.50 | 0.30 | 0.30 | 0.50 | 0.30 | 0.30 | 1.00 | 0.38 | 0.23 | 0.73 |
| Gliclazide 80 mg tablet | 0.30 | 0.30 | 0.35 | 0.20 | 0.10 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.15 | 0.50 |
| Prednisolone 5 mg tablet | 0.55 | 0.50 | 0.64 | 0.60 | 0.45 | 0.65 | 0.59 | 0.55 | 0.65 | 0.58 | 0.50 | 0.60 |
| Promethazine 1 mg/ml syrup | 0.18 | 0.12 | 0.25 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.50 | 0.20 | 0.16 |
| Loratadine 10 mg tablet | 0.08 | 0.06 | 0.09 | 0.09 | 0.07 | 0.10 | 0.07 | 0.07 | 0.06 | 0.07 | 0.06 | 0.09 |
| Simvastatin 20 mg tablet | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |

| **Retail prices were medicine price sampled through the Medicine Price Monitoring Survey (MPMS) from various sites such as community pharmacy and private hospitals in Malaysia; RM Ringgit Malaysia** |
acceptable price markup following previous reported study in private healthcare sector [16]. Many factors contribute to making the MPR > 2.5. However, those worth our attention were location and type of manufacturer. The medicine price disparity between urban and rural areas may hinge on issues related to market segmentation. Segmentation can be welfare-enhancing, as suppliers are able to disaggregate the demand into segments of potential customers and charge according to willingness-to-pay [23]. However, it may also result in price discrimination with some consumers being charged more than they are willing to pay [23]. This may affect the affordability of medicines to consumers and compromise their health. The disparity between medicine prices in urban and rural Malaysia could be overcome by introducing regulations on price markup along the pharmaceutical supply chain. The regulations must consider the additional overhead cost, distribution charges, and profits in urban and rural areas [24].

Medicines from local manufacturers were more likely to have an MPR > 2.5 than those from foreign manufacturers. Although foreign manufacturers such as China and India are able to offer large volumes of medicines at low cost, supporting local manufacturers may be a better approach.

### Table 5

Factors that may influence medicines retail price of MPR > 2.5 in private healthcare sector in Malaysia

| Condition     | MPR ≤ 2.5 (n = 2025, n (%)<sup>a</sup>) | MPR > 2.5 (n = 2325, n (%))<sup>a</sup> | Univariate analysis (n = 2527) | Wald's χ² (df) | P-value | Adj. OR (95% CI) | Wald's χ² (df) | P-value |
|---------------|----------------------------------------|----------------------------------------|-------------------------------|----------------|---------|----------------|----------------|---------|
| Crude OR (95% CI) | Wald's χ² | P-value | Crude OR (95% CI) | Wald's χ² | P-value |
| Condition     |            |          | Condition     |            |          | Condition     |            |          |
| Acute         | 99 (11.3)  | 774 (88.7) | 1.00          | 1.00      | 2.05 (1.46, 2.70) | 16.84 (1)  | <0.001  | 0.48 (0.34, 0.69) | 15.86 (1)  | <0.001  |
| Chronic       | 103 (6.2)  | 1551 (93.8) | 1.93 (1.44, 2.57) | 19.76 (1) | <0.001  | 0.24 (0.15, 0.37) | 39.81 (1)  | <0.001  |
| Type of medicine | Innovator brands | 32 (3.6)  | 851 (96.4) | 1.00      | 1.00      | 3.86 (2.61, 5.71) | 45.88 (1)  | <0.001  |
| Generic       | 170 (10.3) | 1474 (89.7) | 0.33 (0.22, 0.48) | 32.22 (1) | <0.001  | 0.24 (0.15, 0.37) | 39.81 (1)  | <0.001  |
| Manufacturer  | Import      | 149 (8.8)  | 1542 (91.3) | 1.00      | 1.00      | 3.86 (2.61, 5.71) | 45.88 (1)  | <0.001  |
| Local         | 53 (6.3)   | 783 (93.7)  | 1.43 (1.03, 1.98) | 4.61 (1)  | 0.032    | 3.86 (2.61, 5.71) | 45.88 (1)  | <0.001  |
| Region        | Peninsular  | 161 (8.7)  | 1686 (91.3) | 1.00      | 1.00      | 3.86 (2.61, 5.71) | 45.88 (1)  | <0.001  |
| East Malaysia | 41 (6.0)   | 639 (94.0)  | 1.49 (1.04, 2.12) | 4.83 (1)  | 0.028    | 1.84 (1.26, 2.68) | 10.32 (1)  | <0.001  |
| Type of Facility | Community Pharmacy | 179 (8.3)  | 1984 (91.3) | 1.00      | 1.00      | 3.86 (2.61, 5.71) | 45.88 (1)  | <0.001  |
| Private Hospital | 23 (6.3)  | 341 (93.7)  | 1.34 (0.85, 2.09) | 1.61 (1)  | 0.200    | –                  | –              | –      |
| Location      | Urban       | 152 (7.1)  | 1975 (92.9) | 1.00      | 1.00      | 3.86 (2.61, 5.71) | 45.88 (1)  | <0.001  |
| Rural         | 50 (12.5)  | 350 (87.5)  | 0.54 (0.38, 0.76) | 12.77 (1) | <0.001  | 0.48 (0.34, 0.69) | 15.86 (1)  | <0.001  |
| Form          | Tablet      | 161 (6.9)  | 2181 (93.1) | 1.00      | 1.00      | 3.86 (2.61, 5.71) | 45.88 (1)  | <0.001  |
| Other form    | 41 (22.2)  | 144 (77.8)  | 0.26 (0.18, 0.38) | 47.95 (1) | <0.001  | 0.20 (0.13, 0.32) | 51.53 (1)  | <0.001  |
| PSD Wholesale | 5.94<sup>d</sup> | 15.70<sup>d</sup> | 1.58 (1.27, 1.96) | 17.29 (1) | <0.001  | –                  | –              | NS  |
| PSD RRP       | 8.60<sup>d</sup> | 20.84<sup>d</sup> | 1.47 (1.25, 1.74) | 20.96 (1) | <0.001  | 1.52 (1.17, 1.98) | 10.03 (1)  | <0.001  |
| MPMS Wholesale | 5.21<sup>d</sup> | 11.96<sup>d</sup> | 1.36 (1.09, 1.69) | 7.17 (1)  | 0.001   | 0.72 (0.55, 0.93) | 6.10 (1)    | 0.013   |

Abbreviations: MPR median price range, OR odds ratio, CI Confidence interval, NS Non-significant, PSD Pharmaceutical Service Division, RRP Recommended Retail Price, MPMS Medicine Price Monitoring Survey.

Notes: <sup>a</sup> The percentage is reported by row, adding up to 100% based on available information; <sup>d</sup> Median price over IRP; <sup>e</sup> IQR of price over IRP.
systemic approach for improving access to medicines [25]. Some of the advantages of having pharmaceuticals locally manufactured include faster delivery, ability to adapt medicines to local needs, and sufficient supply capacity in emergencies such as outbreaks. It also supports the country’s industrialization and creates new jobs. The higher medicine retail prices declared by local manufacturers may be attributed to the size of the companies. They are usually small and medium-sized companies that cater only to the domestic market, and higher profit margins are vital to their survival [5, 26]. To keep medicine prices competitive, the government may consider providing incentives to local manufacturers. For instance, in Vietnam, a national policy prioritizing the purchase of domestically produced medicines has been imposed [27]. Other approaches include reducing corporate tax rates, providing soft loans, creating an investment-friendly environment, and increasing infrastructure development [28].

There are a few limitations to this study. First, the MPMS only included medicine prices sampled from community pharmacies and a limited number of private hospitals in Malaysia. It did not include the medicine prices from clinics of dispensing doctors. As such, the generalization of the present results to all distribution channels must be done cautiously. In addition, the medicine prices declared to the PSD did not disclose discount and bonus schemes. Since this type of procurement arrangement is usually confidential, it would be difficult to obtain true wholesale prices. In addition, the sample used for this study includes yearly medicine prices for the 5-year period for several pharmaceuticals, but the trend of retail pricing was only applicable to 15 medicine brands.

Conclusion
The declaration of medicine prices was found to have a significant association with retail prices. Thus, the disclosed prices would serve as a useful reference for consumers when purchasing medicines in private healthcare settings. Several factors were found to influence the MPR of retail medicine prices, and could be addressed by several mechanisms. However, the government of Malaysia still must identify and implement strategies to increase medicine price transparency practice by pharmaceutical industry. This may include a regulatory policy that enforces price declaration and medicine price control mechanisms for the private healthcare sector. Results from research on medicine price transparency practices in other countries might provide useful information and guide policy regulation in Malaysia. In addition, future studies should explore the stakeholders’ views on the potential impact of policy regulations aimed at increasing medicine price transparency, price control, or both in the private healthcare sector in Malaysia.

Additional file

Additional file 1: Appendix 1: List of medicines included in the study with indication for chronic and acute condition. (DOCX 26 kb)

Acknowledgements
The authors wish to thank Malaysia’s Director General of Health and Ministry of Health for permission to produce this paper. We would also like to thank the Pharmaceutical Service Division for supporting this study and its Medicine Price Branch for providing and collecting the data used for the analyses.

Funding
The study received financial support from the Fundamental Research Grants Scheme by the Ministry of Higher Education of Malaysia (FRGS/1/2018/5503/UKM/03/2).

Availability of data and materials
The dataset used in this study was obtained from the Pharmaceutical Services Division of Malaysia’s Ministry of Health on reasonable request and with permission from Malaysia’s Director General of Health.

Authors’ contributions
NSA, EMH and MMB conceptualized the study, performed analysis and interpretation of data. NSA did the data collection, NSA, EMH and MMB contributed in manuscript writing and reviewed. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Medical Research and Ethics Committee of Malaysia’s Ministry of Health (reference number, NMRR-17-720-34,389 (IRI)).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia. 2Pharmaceutical Services Division, Ministry of Health Malaysia, 46350 Petaling Jaya, Selangor, Malaysia.

Received: 28 December 2018 Accepted: 8 April 2019
Published online: 03 July 2019

References
1. Thomas S, Beh L, Bin NR. Health care delivery in Malaysia: changes, challenges and champions. J Public Health Africa. 2011;2(9):7–7.
2. Malaysian Investment Development Authority. Medical and healthcare services: Malaysia Investment in the Services Sector. 2017. Available at: http://www.mida.gov.my/home/administrator/system_files/modules/photo/uploads/20170915172756_BOOKLET%20MEDICAL%20AND%20HEALTHCARE%20SERVICES.pdf. Accessed 10 Feb 2019.
3. Ministry of Health Malaysia. Malaysia national health Accounts health expenditure report 1997-2013. Putrajaya: 2015.
4. Ministry of Health Malaysia. Malaysia National Health Accounts: Health expenditure report 1997-2015. Putrajaya; 2015. Available at: http://jenjehor.moh.gov.my/bmv/uploads/penerbitan/MNH%201997-2015.pdf. Accessed 2 May 2019.
5. Hassali MA, Tan CS, Wong ZY, Saleem F, Akrasheedy AA. Pharmaceutical pricing in Malaysia. In: Babar Z-U-D, editor. Pharmaceutical prices in the 21st century. Cham: Springer International Publishing; 2015. p. 171–88.
6. Babar ZUD, Ibrahim MM, Singh H, Bukhari NI, Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007;4(4):e66–75.
7. Hassali MA, Shafie AA, Babar ZUD, Khan TM. A study comparing the retail drug prices between northern Malaysia and Australia. J Pharm Heal Serv Res. 2012;3:103–7.

8. Wiedenmayer K. Access to medicines medicine supply: lessons learnt in Tanzania and Mozambique. Switzerland; 2004. Available at: http://apps.who.int/medicinedocs/documents/s18422en/s18422en.pdf. Accessed 10 Feb 2019.

9. Pharmaceutical Services Division. Malaysian National Medicine Policy. 2012. Available at: https://www.pharmacy.gov.my/v2/sites/default/files/document-upload/buku-dunas.pdf. Accessed 10 Feb 2019.

10. Morgan SG, Thomson PA, Daw JR, Friesen MK. Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Health Policy. 2013;112:248–54.

11. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HGM, Laing R. Differences in external price referencing in Europe-a descriptive overview. Health Policy (New York). 2012;104:50–60.

12. Hinsch M, Kaddar M, Schmitt S. Enhancing medicine price transparency through price information mechanisms. Glob Health. 2014;10:34.

13. Ahmad NS, Islahudin F. Affordability of essential medicine prices in Malaysia’s private health sector. Patient Prefer Adherence. 2018;12:231–7.

14. World Health Organization and Health Action International. Medicine prices-a new approach to measurement: World Health Organization and health action international; 2003. Available at: https://apps.who.int/iris/bitstream/handle/10665/67911/WHO_EDM_PAR_2003.2.pdf?sequence=1&isAllowed=y. Accessed 19 Apr 2019.

15. Management Sciences for Health WHO. International drug Price Indicator guide. Cambridge: management sciences for health; 2010.

16. Susanne G, Margaret E, Noguchi Nakae LR. Price, availability and affordability: an international comparison of chronic disease medicines. Cairo; 2006 Available at: http://haiweb.org/wp-content/uploads/2015/08/Price-Availability-Affordability-An-International-Comparison-of-Chronic-Disease-Medicines.pdf. Accessed 2 May 2019.

17. Bangalee V, Suleman F. Evaluating the effect of a proposed logistics fee cap on pharmaceuticals in South Africa - a pre and post analysis. BMC Health Serv Res. 2015;15:522.

18. Nguyen TA, Knight R, Mant A, Cao QM, Brooks G. Medicine pricing policies: lessons from Vietnam. South Med Rev. 2010;3:12–9.

19. Silvia EM, Schneeveiss S, Thomas S. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21:89–103.

20. Shafie AA, Hassali MA. Price comparison between innovator and generic medicines sold by community pharmacies in the state of Penang, Malaysia. J Generic Med. 2008;6:35–42.

21. Sookrung W, Yoongthong W, Suwatanapreeda S, Chanjaruporn F. Medicine prices in Thailand: a result of no medicine pricing policy, vol. 2; 2009. p. 10–4.

22. Cameron A, Even M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:240–9.

23. Russo G, McPake B. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings. Health Policy Plan. 2010;25:70–84.

24. World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies. 2015.

25. Preker AS, Attridge JS. Improving access to medicines in developing countries: application of new institutional economics to the analysis of manufacturing and distribution issues. Washington DC; 2005. Available at: https://openknowledge.worldbank.org/bitstream/handle/10986/13668/320380AttridgeImprovingAccessFinal.pdf?sequence=1&isAllowed=y. Accessed 2 May 2019.

26. Malaysia Competition Commission. Market Review on Priority Sector Under Competition Act 2010 Pharmaceutical sector. 2017.

27. Angelino A, Khanh DT, Ha N, Pham T. Pharmaceutical industry in Vietnam: sluggish sector in a growing market. Int J Environ Res Public Health. 2017;14.

28. Dong J, Mirza Z. Supporting the production of pharmaceuticals in Africa. Bull World Health Organ. 2016;94:71–2.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions